---
title: "Thermo Fisher Scentific | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 10.86 B"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251224420.md"
published_at: "2025-08-01T14:43:11.000Z"
---

# Thermo Fisher Scentific | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 10.86 B

Revenue: As of FY2025 Q2, the actual value is USD 10.86 B, beating the estimate of USD 10.68 B.

EPS: As of FY2025 Q2, the actual value is USD 4.28, beating the estimate of USD 3.9967.

EBIT: As of FY2025 Q2, the actual value is USD 1.709 B.

### Life Sciences Solutions

-   **Revenues**: $2,499 million for the three months ended June 28, 2025, a 6% increase from $2,355 million in the same period in 2024.
-   **Segment Income**: $919 million for the three months ended June 28, 2025, a 6% increase from $865 million in the same period in 2024.
-   **Segment Income Margin**: 36.8% for the three months ended June 28, 2025, compared to 36.7% in the same period in 2024.

### Analytical Instruments

-   **Revenues**: $1,728 million for the three months ended June 28, 2025, a 3% decrease from $1,782 million in the same period in 2024.
-   **Segment Income**: $325 million for the three months ended June 28, 2025, a 26% decrease from $439 million in the same period in 2024.
-   **Segment Income Margin**: 18.8% for the three months ended June 28, 2025, compared to 24.6% in the same period in 2024.

### Specialty Diagnostics

-   **Revenues**: $1,134 million for the three months ended June 28, 2025, a 2% increase from $1,117 million in the same period in 2024.
-   **Segment Income**: $306 million for the three months ended June 28, 2025, a 3% increase from $299 million in the same period in 2024.
-   **Segment Income Margin**: 27.0% for the three months ended June 28, 2025, compared to 26.7% in the same period in 2024.

### Laboratory Products and Biopharma Services

-   **Revenues**: $5,995 million for the three months ended June 28, 2025, a 4% increase from $5,758 million in the same period in 2024.
-   **Segment Income**: $825 million for the three months ended June 28, 2025, an 11% increase from $745 million in the same period in 2024.
-   **Segment Income Margin**: 13.8% for the three months ended June 28, 2025, compared to 12.9% in the same period in 2024.

### Outlook

Thermo Fisher Scientific Inc. expects its GAAP effective tax rate in 2025 to be between 6% and 8% based on currently forecasted rates of profitability in the countries in which the company conducts business and expected generation of foreign tax credits.

### Related Stocks

- [TMO.US - Thermo Fisher Scentific](https://longbridge.com/en/quote/TMO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 赛默飞世尔｜8-K：2025 财年 Q4 营收 122 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/274138338.md) |
| Prospera Financial Services Inc 减少了其在赛默飞世尔公司的股票持有量 | Prospera Financial Services Inc 在第三季度减少了对赛默飞世尔的持股，降幅为 25.9%，目前持有 14,407 股，市值为 699 万美元。其他机构投资者也调整了他们的持股，Brighton Jones LL | [Link](https://longbridge.com/en/news/275597600.md) |
| 达利欧万字长文：旧秩序已死，世界重回 “丛林法则”，贸易战和资本战将成常态 | 达利欧宣告世界进入 “大周期” 第六阶段：1945 年后的世界秩序已瓦解，强权即公理，大国冲突将回归原始权力博弈，贸易战、技术战、资本战将常态化并可能升级为军事冲突。慕尼黑安全会议共识印证这一判断：旧秩序已不复存在，欧洲安全架构失效。达利欧 | [Link](https://longbridge.com/en/news/276003775.md) |
| 财报、指引皆超预期，“AI 应用热股” Applovin 股价依旧大跌 | 财报显示，AppLovin Q4 营收 16.6 亿美元（+66%）及 EBITDA 利润率（84%）均超预期，但因市场担忧 AI 颠覆及 Meta 竞争，股价盘后大跌。公司 CEO 强硬回应称市场情绪与现实脱节，强调 AI 带来的内容爆发 | [Link](https://longbridge.com/en/news/275682023.md) |
| “医药春晚” 上，英伟达详细论述 “AI 医疗怎么干” | 摩根大通表示，英伟达在 AI 医疗进行 “全栈式” 布局，英伟达正在构建一个从芯片到工具再到领域模型的闭环，即所谓的 “干实验室 - 湿实验室” 飞轮，同时 AI 正在从 “试点” 走向 “受雇”，美国医疗行业商业 AI 部署速度是整体经济 | [Link](https://longbridge.com/en/news/272487651.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.